ELIL J3L-MC-EZEJ Lp(a) CCTA (ELS)

About this study:

This study is for people who have high levels of lipoprotein(a), also called Lp(a), a type of cholesterol in the blood that can increase the risk of heart disease. Researchers are studying whether a medication called lepodisiran can lower Lp(a) and help reduce harmful buildup (plaque) in the heart’s blood vessels.

You may qualify if:

• Your Lp(a) is high (≥175)

• You have heart disease or are at high risk for it
• A heart scan (CCTA) shows plaque in your arteries
• Your cholesterol medications have been stable for at least 8 weeks

You may NOT qualify if:

• You had a recent heart attack or stroke (within 60 days)

• You have serious kidney or heart failure
• You’ve had bypass surgery (CABG)
• You’re planning a heart procedure soon (stent, surgery, etc.)
• You’ve received special treatments to lower Lp(a)
• You can’t safely undergo a CT scan (contrast allergy, etc.)

Why participate?

• Help advance research in heart disease prevention
• Compensation may be available (if applicable) )

Study Details: 

Location: Jacksonville, FL 

All study-related care is provided at no cost to you or your insurance company.

About this study: 

This extension study looks at the long-term safety and effectiveness of remibrutinib in people with CSU(Chronic Spontaneous Uticaria“Hives”   who completed a prior study, while also allowing continued access to the medication after the Phase 3 studies, when appropriate.

Who can join:

• You must sign a consent form before any study procedures.

• You must be 18 years or older.
• You must have completed a previous remibrutinib study.
• You should be willing and able to follow the study visits and instructions.

Who cannot join:

• You have a high risk of bleeding or a bleeding disorder.

• You have a history of stomach or intestinal bleeding.
• You need to take blood thinners or medications that affect clotting.
• You have current or past liver disease.
• You have other serious health conditions (such as heart, lung, kidney, immune, or mental health conditions) that could make participation unsafe or affect study results.

Why participate?

• Help advance research in heart disease prevention
• Compensation may be available (if applicable) )

Study Details: 

Location: Jacksonville, FL 

All study-related care is provided at no cost to you or your insurance company.

About this study: 

This study is testing how well new medicines (CagriSema and cagrilintide) help children and teens lose weight.

Who can join?

• Ages 8 to under 18

• Higher body weight for age/height
• Tried diet and exercise for 3+ months without enough success
• Weigh over 45 kg (99 lbs)
• Parent/guardian consent + child agreement
• Normal lab tests

If they have type 2 diabetes:

• Controlled blood sugar

• Only on lifestyle changes or stable metformin

Who cannot join?

• Used weight-loss meds in last 90 days

• Had recent weight-loss surgery/devices

• Uncontrolled thyroidor genetic/hormonal obesity
• Big weight change(>5%) in last 3 months
• Type 1 diabetes

Extra exclusions:

• Without T2D: high blood sugar or diabetes meds

• With T2D: frequent low blood sugar, certain antibodies, other diabetes meds, or serious eye problems

Why participate?

• Help advance research in heart disease prevention
• Compensation may be available (if applicable) )

Study Details: 

Location: Jacksonville, FL 

All study-related care is provided at no cost to you or your insurance company.